Prelude Therapeutics Incorporated (PRLD) Stock Forecast
Data as of Aug 8, 2026Healthcare · Current price $4.92 (+5.02%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
PRLD vs Sector & Market
| Metric | PRLD | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.00 | 2.25 | 2.42 |
| Analyst Count | 2 | 8 | 18 |
| Target Upside | +62.8% | +16286.4% | +14.7% |
| P/E Ratio | -2.78 | 3.59 | 36.06 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-09-30 | $50M | $50M | $50M | 1 |
| 2026-12-31 | $7M | $7M | $7M | 1 |
| 2027-12-31 | $100M | $100M | $100M | 1 |
| 2028-12-31 | $200M | $200M | $200M | 1 |
| 2029-12-31 | $100M | $100M | $100M | 1 |
| 2030-12-31 | $100M | $100M | $100M | 1 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-09-30 | $0.39 | $0.39 | $0.39 | 1 |
| 2026-12-31 | $-0.27 | $-0.27 | $-0.27 | 1 |
| 2027-12-31 | $-0.32 | $-0.32 | $-0.32 | 1 |
| 2028-12-31 | $0.09 | $0.09 | $0.09 | 1 |
| 2029-12-31 | $-0.03 | $-0.03 | $-0.03 | 1 |
| 2030-12-31 | $0.37 | $0.37 | $0.37 | 1 |
Frequently Asked Questions
What is the analyst consensus for PRLD?
The consensus among 2 analysts covering Prelude Therapeutics Incorporated (PRLD) is Buy with an average price target of $8.00.
What is the highest price target for PRLD?
The highest analyst price target for PRLD is $8.00.
What is the lowest price target for PRLD?
The lowest analyst price target for PRLD is $8.00.
How many analysts cover PRLD?
2 analysts have issued ratings for Prelude Therapeutics Incorporated in the past 12 months.
Is PRLD a buy or sell right now?
Based on 2 analyst ratings, PRLD has a consensus rating of Buy (2.00/5) with a +62.8% upside to the consensus target of $8.00.
What are the earnings estimates for PRLD?
Analysts estimate PRLD will report EPS of $0.39 for the period ending 2026-09-30, with revenue estimated at $50M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.